ticlopidine has been researched along with Chronic Kidney Diseases in 40 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dual clopidogrel-aspirin therapy was associated with a marked reduction in new strokes compared with the therapy of aspirin alone in patients with normal renal function (hazard ratio, 0." | 9.22 | Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Wu, Y; Zhao, X; Zhou, Y, 2016) |
| "The optimal loading dose of clopidogrel in patients with chronic kidney disease who undergo primary percutaneous coronary intervention for ST-segment elevation myocardial infarction has not been investigated." | 9.16 | Impact of Clopidogrel loading dose in patients with chronic kidney disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. ( Ahn, YK; Chae, IH; Chae, SC; Cho, MC; Hong, TJ; Hur, SH; Jang, YS; Jeong, MH; Kim, JY; Kim, YJ; Moon, JH; Park, SJ; Seong, IW; Seung, KB; Yoon, JH, 2012) |
| "Clinical and genetic factors had a differential effect on a P2Y12 inhibitor reactivity with clopidogrel and prasugrel in patients with coronary artery disease." | 8.12 | Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel. ( Ariyoshi, N; Kitahara, H; Kobayashi, Y; Nishi, T; Ohno, Y; Saito, Y; Wakabayashi, S, 2022) |
| "A total of 129 noncardiogenic ischemic stroke patients receiving 75 mg/day of clopidogrel for ≥1 week were evaluated." | 7.80 | Response to clopidogrel and its association with chronic kidney disease in noncardiogenic ischemic stroke patients. ( Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagamine, Y; Ohe, Y; Sano, H; Tanahashi, N, 2014) |
| "The aim of the present study was to evaluate clopidogrel treatment after incident myocardial infarction (MI) in patients with and without chronic kidney disease (CKD)." | 7.80 | Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. ( Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C, 2014) |
| "Clopidogrel could decrease mortality and improve cardiovascular outcomes without increasing risk of bleeding in ACS patients with CKD." | 7.79 | Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. ( Chang, SC; Chiang, FT; Hsin, HT; Hwang, JJ; Kuo, CT; Lai, WT; Li, AH; Lin, TH; Wang, CL, 2013) |
| "Dual clopidogrel-aspirin therapy was associated with a marked reduction in new strokes compared with the therapy of aspirin alone in patients with normal renal function (hazard ratio, 0." | 5.22 | Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Wu, Y; Zhao, X; Zhou, Y, 2016) |
| "We evaluated the impact of clopidogrel 150 mg/d in patients with chronic kidney disease (CKD) having clopidogrel resistance (CR) after percutaneous coronary intervention (PCI); 1076 consecutive patients with coronary artery disease (CAD) having CKD were enrolled." | 5.20 | High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. ( Han, H; Li, Y; Liang, J; Liu, W; Liu, Y; Shi, D; Wang, Z; Yang, L; Zhang, L; Zhao, Y; Zhou, Y, 2015) |
| "The optimal loading dose of clopidogrel in patients with chronic kidney disease who undergo primary percutaneous coronary intervention for ST-segment elevation myocardial infarction has not been investigated." | 5.16 | Impact of Clopidogrel loading dose in patients with chronic kidney disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. ( Ahn, YK; Chae, IH; Chae, SC; Cho, MC; Hong, TJ; Hur, SH; Jang, YS; Jeong, MH; Kim, JY; Kim, YJ; Moon, JH; Park, SJ; Seong, IW; Seung, KB; Yoon, JH, 2012) |
| "Clopidogrel in mild or moderate CKD patients may not have the same beneficial effect as it does in patients with normal renal function, but was not associated with a greater relative risk of bleeding based on renal function." | 5.13 | The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Berger, PB; Best, PJ; Brennan, DM; Califf, RM; Dasgupta, A; Steinhubl, SR; Szczech, LA; Topol, EJ, 2008) |
| " Laboratory and clinical data have convincingly shown the benefit of P2Y12 inhibition combined with aspirin in patients with acute coronary syndrome (ACS)/undergoing percutaneous coronary intervention (PCI)." | 4.90 | p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa. ( Alexopoulos, D, 2014) |
| "Clinical and genetic factors had a differential effect on a P2Y12 inhibitor reactivity with clopidogrel and prasugrel in patients with coronary artery disease." | 4.12 | Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel. ( Ariyoshi, N; Kitahara, H; Kobayashi, Y; Nishi, T; Ohno, Y; Saito, Y; Wakabayashi, S, 2022) |
| " Cox proportional hazard regression models were developed to evaluate the predictors of LGIB with adjustments for age, gender, comorbidities including coronary artery disease, ischaemic stroke, diabetes, hypertension, chronic kidney disease, liver cirrhosis, chronic obstructive pulmonary disease, dyslipidemia, uncomplicated peptic ulcer disease, history of peptic ulcer bleeding, and concomitant use of clopidogrel, ticlopidine, warfarin, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 inhibitors, steroids, proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RAs), nitrates, alendronate, selective serotonin reuptake inhibitors (SSRIs) and calcium channel blockers." | 3.85 | The risk of lower gastrointestinal bleeding in low-dose aspirin users. ( Chen, WC; Chuah, SK; Hsu, PI; Huang, YT; Lin, KH; Sun, WC; Tsai, TJ; Wu, DC, 2017) |
| "To describe contemporary trends of P2Y12 inhibitor use in patients with acute coronary syndrome (ACS) and comorbid diabetes mellitus (DM) and/or chronic kidney disease (CKD) who have a higher risk of recurring ACS and may benefit from treatment with higher efficacy third-generation agents (prasugrel and ticagrelor)." | 3.85 | Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease. ( Desai, RJ; Gagne, JJ; Mogun, H; Spoendlin, J, 2017) |
| "Scarce and conflicting evidence exists on whether clopidogrel is effective and whether dual antiplatelet treatment (DAPT) is safe in patients with acute coronary syndrome and chronic kidney disease (CKD)." | 3.85 | Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. ( Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C, 2017) |
| "A total of 129 noncardiogenic ischemic stroke patients receiving 75 mg/day of clopidogrel for ≥1 week were evaluated." | 3.80 | Response to clopidogrel and its association with chronic kidney disease in noncardiogenic ischemic stroke patients. ( Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagamine, Y; Ohe, Y; Sano, H; Tanahashi, N, 2014) |
| "The aim of the present study was to evaluate clopidogrel treatment after incident myocardial infarction (MI) in patients with and without chronic kidney disease (CKD)." | 3.80 | Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. ( Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C, 2014) |
| " Many medications (warfarin, heparin, clopidogrel) or physiological factors (elevated International Normalized Ratio [INR], thrombocytopenia, uremia) increase the risk for bleeding." | 3.79 | The safety of thoracentesis in patients with uncorrected bleeding risk. ( Araujo, KL; Argento, AC; Murphy, TE; Pisani, MA; Puchalski, JT, 2013) |
| "Clopidogrel could decrease mortality and improve cardiovascular outcomes without increasing risk of bleeding in ACS patients with CKD." | 3.79 | Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. ( Chang, SC; Chiang, FT; Hsin, HT; Hwang, JJ; Kuo, CT; Lai, WT; Li, AH; Lin, TH; Wang, CL, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.00) | 29.6817 |
| 2010's | 34 (85.00) | 24.3611 |
| 2020's | 4 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verdoia, M | 2 |
| Nardin, M | 2 |
| Gioscia, R | 1 |
| Suryapranata, H | 2 |
| Kedhi, E | 1 |
| Rognoni, A | 1 |
| DE Luca, G | 3 |
| Jain, N | 2 |
| Corken, A | 1 |
| Arthur, JM | 1 |
| Ware, J | 1 |
| Arulprakash, N | 1 |
| Dai, J | 1 |
| Phadnis, MA | 1 |
| Davis, O | 1 |
| Rahmatallah, Y | 1 |
| Mehta, JL | 1 |
| Hedayati, SS | 2 |
| Smyth, S | 1 |
| Ndulue, CN | 1 |
| Jisieike-Onuigbo, NN | 1 |
| Okwesa, NJ | 1 |
| Anyanor, A | 1 |
| Ozuemba, BC | 1 |
| Osakwe, N | 1 |
| Oguejiofor, F | 1 |
| Eze, H | 1 |
| Kalu, AO | 1 |
| Odenigbo, CU | 1 |
| Saito, Y | 1 |
| Nishi, T | 1 |
| Wakabayashi, S | 1 |
| Ohno, Y | 1 |
| Kitahara, H | 1 |
| Ariyoshi, N | 1 |
| Kobayashi, Y | 1 |
| Chen, WC | 1 |
| Lin, KH | 1 |
| Huang, YT | 1 |
| Tsai, TJ | 1 |
| Sun, WC | 1 |
| Chuah, SK | 1 |
| Wu, DC | 1 |
| Hsu, PI | 1 |
| Baber, U | 1 |
| Chandrasekhar, J | 1 |
| Sartori, S | 1 |
| Aquino, M | 1 |
| Kini, AS | 1 |
| Kapadia, S | 1 |
| Weintraub, W | 1 |
| Muhlestein, JB | 1 |
| Vogel, B | 1 |
| Faggioni, M | 1 |
| Farhan, S | 1 |
| Weiss, S | 1 |
| Strauss, C | 1 |
| Toma, C | 1 |
| DeFranco, A | 1 |
| Baker, BA | 1 |
| Keller, S | 1 |
| Effron, MB | 1 |
| Henry, TD | 1 |
| Rao, S | 1 |
| Pocock, S | 1 |
| Dangas, G | 1 |
| Mehran, R | 1 |
| Desai, RJ | 1 |
| Spoendlin, J | 1 |
| Mogun, H | 1 |
| Gagne, JJ | 1 |
| Wang, H | 1 |
| Qi, J | 1 |
| Li, Y | 2 |
| Tang, Y | 1 |
| Li, C | 1 |
| Li, J | 1 |
| Han, Y | 1 |
| Fischer, MJ | 1 |
| Ho, PM | 1 |
| McDermott, K | 1 |
| Lowy, E | 1 |
| Parikh, CR | 1 |
| Puchalski, JT | 1 |
| Argento, AC | 1 |
| Murphy, TE | 1 |
| Araujo, KL | 1 |
| Pisani, MA | 1 |
| Lin, TH | 1 |
| Lai, WT | 1 |
| Hsin, HT | 1 |
| Li, AH | 1 |
| Wang, CL | 1 |
| Kuo, CT | 1 |
| Hwang, JJ | 1 |
| Chiang, FT | 1 |
| Chang, SC | 1 |
| Lin, CC | 1 |
| Hu, HY | 1 |
| Luo, JC | 1 |
| Peng, YL | 1 |
| Hou, MC | 1 |
| Lin, HC | 1 |
| Lee, FY | 1 |
| Alexopoulos, D | 1 |
| Maruyama, H | 1 |
| Fukuoka, T | 1 |
| Deguchi, I | 1 |
| Ohe, Y | 1 |
| Kato, Y | 1 |
| Horiuchi, Y | 1 |
| Hayashi, T | 1 |
| Nagamine, Y | 1 |
| Sano, H | 1 |
| Tanahashi, N | 1 |
| Mangiacapra, F | 1 |
| Cavallari, I | 1 |
| Barbato, E | 1 |
| Ricottini, E | 1 |
| Patti, G | 1 |
| Vizzi, V | 1 |
| D'Ambrosio, A | 1 |
| De Bruyne, B | 1 |
| Wijns, W | 1 |
| Di Sciascio, G | 1 |
| Parodi, G | 1 |
| Bellandi, B | 1 |
| Comito, V | 1 |
| Valenti, R | 1 |
| Marcucci, R | 1 |
| Carrabba, N | 1 |
| Migliorini, A | 1 |
| Ramazzotti, RN | 1 |
| Gensini, GF | 1 |
| Abbate, R | 1 |
| Antoniucci, D | 1 |
| Gabrielli, A | 1 |
| Bouatou, Y | 1 |
| Saudan, P | 1 |
| Liang, J | 1 |
| Wang, Z | 1 |
| Shi, D | 1 |
| Liu, Y | 1 |
| Zhao, Y | 1 |
| Han, H | 1 |
| Liu, W | 1 |
| Zhang, L | 1 |
| Yang, L | 1 |
| Zhou, Y | 2 |
| Park, Y | 1 |
| Jung, JM | 1 |
| Tantry, US | 1 |
| Kim, K | 1 |
| Koh, JS | 1 |
| Park, JR | 1 |
| Hwang, SJ | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Kim, S | 1 |
| Gurbel, PA | 1 |
| Jeong, YH | 1 |
| Blicher, TM | 1 |
| Hommel, K | 1 |
| Kristensen, SL | 1 |
| Torp-Pedersen, C | 1 |
| Madsen, M | 1 |
| Kamper, AL | 1 |
| Olesen, JB | 1 |
| Verma, A | 1 |
| Cairns, JA | 1 |
| Mitchell, LB | 1 |
| Macle, L | 1 |
| Stiell, IG | 1 |
| Gladstone, D | 1 |
| McMurtry, MS | 1 |
| Connolly, S | 1 |
| Cox, JL | 1 |
| Dorian, P | 1 |
| Ivers, N | 1 |
| Leblanc, K | 1 |
| Nattel, S | 1 |
| Healey, JS | 1 |
| Lee, SA | 1 |
| Suh, JW | 1 |
| Park, JJ | 1 |
| Yoon, CH | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Chae, IH | 2 |
| Kim, HS | 1 |
| Kim, SH | 1 |
| Choi, DJ | 1 |
| Siddiqi, OK | 1 |
| Smoot, KJ | 1 |
| Dufour, AB | 1 |
| Cho, K | 1 |
| Young, M | 1 |
| Gagnon, DR | 1 |
| Ly, S | 1 |
| Temiyasathit, S | 1 |
| Faxon, DP | 1 |
| Gaziano, JM | 1 |
| Kinlay, S | 1 |
| Melloni, C | 1 |
| Cornel, JH | 1 |
| Hafley, G | 1 |
| Neely, ML | 1 |
| Clemmensen, P | 1 |
| Zamoryakhin, D | 1 |
| Prabhakaran, D | 1 |
| White, HD | 1 |
| Fox, KA | 1 |
| Ohman, EM | 1 |
| Armstrong, PW | 1 |
| Roe, MT | 1 |
| Barbieri, L | 1 |
| Pergolini, P | 1 |
| Rolla, R | 1 |
| Marino, P | 1 |
| Bellomo, G | 1 |
| Li, X | 1 |
| Adams-Huet, B | 1 |
| Sarode, R | 1 |
| Toto, RD | 1 |
| Banerjee, S | 1 |
| Cavallari, LH | 1 |
| Mason, DL | 1 |
| Crimi, G | 1 |
| Leonardi, S | 1 |
| Costa, F | 1 |
| Adamo, M | 1 |
| Ariotti, S | 1 |
| Valgimigli, M | 1 |
| Muller, C | 1 |
| Messas, N | 1 |
| Perrin, P | 1 |
| Olagne, J | 1 |
| Gautier-Vargas, G | 1 |
| Cognard, N | 1 |
| Caillard, S | 2 |
| Moulin, B | 2 |
| Morel, O | 2 |
| Pan, Y | 1 |
| Wu, Y | 1 |
| Zhao, X | 1 |
| Li, H | 1 |
| Wang, D | 1 |
| Johnston, SC | 1 |
| Liu, L | 1 |
| Wang, C | 1 |
| Meng, X | 1 |
| Wang, Y | 2 |
| Engwenyu, LR | 1 |
| Franchi, F | 1 |
| Rollini, F | 1 |
| Cho, JR | 1 |
| DeGroat, C | 1 |
| Bhatti, M | 1 |
| Alobaidi, Z | 1 |
| Ferrante, E | 1 |
| Jakubowski, JA | 1 |
| Sugidachi, A | 1 |
| Zenni, M | 1 |
| Bass, TA | 1 |
| Angiolillo, DJ | 1 |
| Carrero, JJ | 1 |
| Varenhorst, C | 1 |
| Jensevik, K | 1 |
| Szummer, K | 1 |
| Lagerqvist, B | 1 |
| Evans, M | 1 |
| Spaak, J | 1 |
| Held, C | 1 |
| James, S | 1 |
| Jernberg, T | 1 |
| El-Menyar, A | 1 |
| Hussein, H | 1 |
| Al Suwaidi, J | 1 |
| Cuisset, T | 1 |
| Frere, C | 1 |
| Moro, PJ | 1 |
| Quilici, J | 1 |
| Pons, C | 1 |
| Gaborit, B | 1 |
| Camoin, L | 1 |
| Morange, PE | 1 |
| Bonnet, JL | 1 |
| Alessi, MC | 1 |
| El Ghannudi, S | 1 |
| Jesel, L | 1 |
| Radulescu, B | 1 |
| Meyer, N | 1 |
| Wiesel, ML | 1 |
| Campia, U | 1 |
| Gachet, C | 1 |
| Ohlmann, P | 1 |
| Arai, T | 1 |
| Kawamura, A | 1 |
| Matsubara, Y | 1 |
| Yokoyama, K | 1 |
| Ikeda, Y | 1 |
| Fukuda, K | 1 |
| Murata, M | 1 |
| Kim, JY | 1 |
| Jeong, MH | 1 |
| Moon, JH | 1 |
| Ahn, YK | 1 |
| Chae, SC | 1 |
| Hur, SH | 1 |
| Hong, TJ | 1 |
| Kim, YJ | 1 |
| Seong, IW | 1 |
| Cho, MC | 1 |
| Jang, YS | 1 |
| Yoon, JH | 1 |
| Seung, KB | 1 |
| Park, SJ | 1 |
| Leng, WX | 1 |
| Ren, JW | 1 |
| Cao, J | 1 |
| Cong, YL | 1 |
| Cui, H | 1 |
| Hu, GL | 1 |
| Hu, QQ | 1 |
| Niu, H | 1 |
| Fan, L | 1 |
| Lepor, NE | 1 |
| Best, PJ | 1 |
| Steinhubl, SR | 1 |
| Berger, PB | 1 |
| Dasgupta, A | 1 |
| Brennan, DM | 1 |
| Szczech, LA | 1 |
| Califf, RM | 1 |
| Topol, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vacuum vs Manual Drainage During Unilateral Thoracentesis: A Randomized Trial[NCT03496987] | 100 participants (Actual) | Interventional | 2015-12-01 | Completed | |||
| Pharmacokinetics and Pharmacodynamics of Apixaban in End-stage Renal Disease Patients on Hemodialysis[NCT02672709] | Phase 4 | 7 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| The Effect of Nurse Practitioner-Led Care on Health Related Quality Of Life in Adult Patients With Atrial Fibrillation - A Randomized Trial[NCT02745236] | 150 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment[NCT02294643] | Phase 3 | 220 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin[NCT01768637] | Phase 1 | 48 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589] | Phase 3 | 5,100 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease[NCT03150667] | Phase 4 | 220 participants (Anticipated) | Interventional | 2017-04-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients who had procedure termination prior to complete evacuation of the pleural contents (usually as a result of refractory pain or another symptom that the patient perceived). (NCT03496987)
Timeframe: 5-20 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Manual Drainage | 1 |
| Vacuum Bottle Drainage | 8 |
"Difference in pain between pre-procedural pain and during drainage pain as measured as the difference between a pre-procedural NPSS pain score (range from 0 (no pain) to 10 (maximum pain)). This was asked again during drainage and the difference between the two was recorded. The values ranged from -10 to 10 (with a more negative number representing a decrease in pain and a more positive number representing an increase in pain)~The scale used is called The Numeric Pain Rating Scale. With ratings from 0-10. Zero is the least amount of pain experienced while 10 is the worst pain possible." (NCT03496987)
Timeframe: 5-20 minutes
| Intervention | Pre-post NPRS Pain Scale Score (Mean) |
|---|---|
| Manual Drainage | 0.53 |
| Vacuum Bottle Drainage | 1.43 |
Actual time of drainage in seconds for each patient. (NCT03496987)
Timeframe: 5-20 minutes
| Intervention | seconds (Mean) |
|---|---|
| Manual Drainage | 498.5 |
| Vacuum Bottle Drainage | 318.6 |
Volume of effusion drained (in mL) (NCT03496987)
Timeframe: <20 minutes
| Intervention | milliters (Mean) |
|---|---|
| Manual Drainage | 1023 |
| Vacuum Bottle Drainage | 1143 |
Clinical etiology of effusion (NCT03496987)
Timeframe: <7 days
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Malignant | Paramalignant | Heart Failure | Hepatic Hydrothorax | Post-Cardiothoracic Procedure | Parapneumonic | Unknown | |
| Manual Drainage | 13 | 7 | 7 | 3 | 13 | 3 | 3 |
| Vacuum Bottle Drainage | 8 | 2 | 8 | 5 | 17 | 2 | 8 |
Any complications that occur as a direct result of the procedure. We tracked patients for 7 days after the procedure to capture any complications (which is typical clinical practice) (NCT03496987)
Timeframe: <7 days
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Pneumothorax | Hemothorax | Clinically Significant Pulmonary Edema | |
| Manual Drainage | 0 | 0 | 0 |
| Vacuum Bottle Drainage | 3 | 1 | 1 |
Citrated whole blood was used to measure platelet aggregation induced by agonist (arachidonic acid at 5 mM concentration) using impedance whole blood platelet aggregometry via a Chrono-log aggregometer. Values at baseline (visit 1) was compared between groups with post treatment values (visit 2) after 2 weeks of aspirin treatment (NCT01768637)
Timeframe: 2 weeks
| Intervention | ohms (Median) | |
|---|---|---|
| Baseline | visit 2 | |
| Chronic Kidney Disease | 21.0 | 0 |
| Normal Controls | 18.0 | 0 |
Citrated whole blood was used to measure platelet aggregation induced by agonist (collagen at 2mM concentration) using impedance whole blood platelet aggregometry via a Chrono-log aggregometer. Values at baseline (visit 1) was compared between groups with post treatment values (visit 2) after 2 weeks of aspirin treatment (NCT01768637)
Timeframe: 2 weeks
| Intervention | ohms (Median) | |
|---|---|---|
| Baseline | visit 2 | |
| Chronic Kidney Disease | 28.5 | 19.5 |
| Normal Controls | 25.0 | 19.0 |
Citrated whole blood was used to measure platelet aggregation induced by agonist (adenosine diphosphate at 20mM concentration) using impedance whole blood platelet aggregometry via a Chrono-log aggregometer. Values at baseline (visit 1) and on aspirin (visit 2) was compared between groups with post treatment values (visit 3) after 2 weeks of aspirin and clopidogrel treatment (NCT01768637)
Timeframe: 4 weeks
| Intervention | ohms (Mean) | ||
|---|---|---|---|
| Baseline | visit 2 | visit 3 | |
| Chronic Kidney Disease | 13.5 | 11.0 | 8.0 |
| Normal Controls | 9.0 | 10.0 | 3.0 |
5 reviews available for ticlopidine and Chronic Kidney Diseases
| Article | Year |
|---|---|
p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Diabetic Angiopathies; Huma | 2014 |
[Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?].
Topics: Adenosine; Blood Platelet Disorders; Clopidogrel; Evidence-Based Practice; Humans; Piperazines; Plat | 2014 |
Cardiovascular Pharmacogenomics--Implications for Patients With CKD.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 | 2016 |
Coronary stent thrombosis in patients with chronic renal insufficiency.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Huma | 2010 |
Impact of chronic kidney disease and diabetes on percutaneous coronary intervention outcomes.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Diseases; Clinical | 2006 |
12 trials available for ticlopidine and Chronic Kidney Diseases
23 other studies available for ticlopidine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Impact of renal failure and high-platelet reactivity on major cardiovascular ischemic events among patients with acute coronary syndrome receiving dual antiplatelet therapy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Clopidogrel; Humans; Patient Discharge; Percutaneous | 2023 |
Clopidogrel-induced thrombotic thrombocytopenic purpura: a case report.
Topics: Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purpura, Thrombotic Thrombocytopenic; Renal In | 2023 |
Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus; | 2022 |
The risk of lower gastrointestinal bleeding in low-dose aspirin users.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studi | 2017 |
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Thr | 2017 |
Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cohort Studies; Diabetes Mellitus; Drug Utilization | 2017 |
Chronic kidney disease is associated with adverse outcomes among elderly patients taking clopidogrel after hospitalization for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Female; | 2013 |
The safety of thoracentesis in patients with uncorrected bleeding risk.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Disorders; Clopidogrel; Cohort Studies; D | 2013 |
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Me | 2013 |
Risk factors of gastrointestinal bleeding in clopidogrel users: a nationwide population-based study.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Cohort Studies; Da | 2013 |
Response to clopidogrel and its association with chronic kidney disease in noncardiogenic ischemic stroke patients.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle | 2014 |
Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Electrocardiography; Female; Follow-Up | 2014 |
Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Cohort Studies; | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug-El | 2015 |
Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; | 2016 |
Impaired P2Y12 inhibition by clopidogrel in kidney transplant recipients: results from a cohort study.
Topics: Aged; Clopidogrel; Cohort Studies; Female; Humans; Kidney Transplantation; Male; Middle Aged; Platel | 2016 |
Impact of chronic kidney disease on platelet P2Y
Topics: Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Diabetes Mellitus, Type 2; Dose-R | 2017 |
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Co | 2017 |
Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; | 2010 |
Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Cause of Death; Clop | 2011 |
Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting | 2012 |
Chronic kidney disease--is it a true risk factor of reduced clopidogrel efficacy in elderly patients with stable coronary artery disease?
Topics: Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Creatinine; Female; Hemogl | 2013 |